SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-181344
Filing Date
2023-07-03
Accepted
2023-07-03 16:07:28
Documents
12
Period of Report
2023-06-30
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d431816d8k.htm   iXBRL 8-K 36323
  Complete submission text file 0001193125-23-181344.txt   158451

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA aldx-20230630.xsd EX-101.SCH 2838
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE aldx-20230630_lab.xml EX-101.LAB 17994
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aldx-20230630_pre.xml EX-101.PRE 11253
6 EXTRACTED XBRL INSTANCE DOCUMENT d431816d8k_htm.xml XML 3356
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36332 | Film No.: 231065350
SIC: 2834 Pharmaceutical Preparations